[{"Assets_0_Q2_USD":23606588.0,"CommonStockSharesOutstanding_0_Q2_shares":41376061.0,"EarningsPerShareBasic_1_Q2_USD":-0.04,"EarningsPerShareBasic_2_Q2_USD":-0.12,"EarningsPerShareDiluted_1_Q2_USD":-0.04,"EarningsPerShareDiluted_2_Q2_USD":-0.12,"NetIncomeLoss_1_Q2_USD":-1549087.0,"NetIncomeLoss_2_Q2_USD":-4695746.0,"StockholdersEquity_0_Q2_USD":21486691.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":41159707.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":39761612.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":41159707.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":39761612.0,"Ticker":"AVXL","CIK":"1314052","name":"ANAVEX LIFE SCIENCES CORP.","OfficialName":"Anavex Life Sciences Corp. Common Stock","form":"10-Q","period":"20170331","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"825317693.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20170510"}]